Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer Journal Article
| Authors: | Ilson, D. H.; Wadleigh, R. G.; Leichman, L. P.; Kelsen, D. P. |
| Article Title: | Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer |
| Abstract: | Background: The purpose of the study was to evaluate the efficacy of weekly paclitaxel (Taxol) in advanced esophageal cancer. Patients and methods: One hundred and two patients with advanced esophageal cancer were treated with paclitaxel 80 mg/m2 weekly over a 1-h infusion. One cycle was defined as 4 weeks of therapy. Ninety-five patients were assessable for toxicity and 86 patients who completed at least two cycles of treatment were assessable for response. Sixty-six patients had adenocarcinoma (66%) and 65 patients (68%) had no prior chemotherapy. Results: A median of three cycles was delivered (range 1-11). Partial responses (PRs) were seen in 11 patients [13%, 95% confidence interval (CI) 6% to 20%]. In patients without prior chemotherapy, PRs were seen in 10 patients (15%, 95% CI 6% to 24%), with comparable response in adenocarcinoma (8/50, 16%) and squamous carcinoma (2/15, 13%). Limited response was seen in patients with prior chemotherapy (1/21, 5%). The median duration of response was 172 days. The median survival was 274 days. Therapy was well tolerated with minimal hematologic or grade 3 or 4 toxicity. Conclusion: Weekly paclitaxel has limited activity in esophageal cancer. The median survival, modest activity, and tolerance of therapy indicate that weekly paclitaxel may be an option in patients unable to tolerate combination chemotherapy. © 2007 European Society for Medical Oncology. |
| Keywords: | adult; cancer survival; controlled study; treatment outcome; aged; aged, 80 and over; middle aged; survival analysis; major clinical study; constipation; drug tolerability; neutropenia; squamous cell carcinoma; carcinoma, squamous cell; advanced cancer; diarrhea; drug dose reduction; drug efficacy; drug safety; drug withdrawal; monotherapy; paclitaxel; follow-up studies; adenocarcinoma; edema; drug eruption; infection; multiple cycle treatment; anemia; neuropathy; stomatitis; thrombocytopenia; myalgia; drug administration schedule; antineoplastic agents, phytogenic; dexamethasone; time factors; arthralgia; asthenia; chill; drug hypersensitivity; dyspnea; pneumonia; confidence interval; chemotherapy induced emesis; survival time; thrombosis; drug response; sepsis; hyperbilirubinemia; esophagus cancer; esophageal adenocarcinoma; alopecia; infusions, intravenous; esophageal neoplasms; esophageal cancer; drug indication; diphenhydramine; cimetidine; foot disease; weekly paclitaxel |
| Journal Title: | Annals of Oncology |
| Volume: | 18 |
| Issue: | 5 |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2007-05-01 |
| Start Page: | 898 |
| End Page: | 902 |
| Language: | English |
| DOI: | 10.1093/annonc/mdm004 |
| PUBMED: | 17351256 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 11" - "Export Date: 17 November 2011" - "CODEN: ANONE" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work